Although the advent of PD1/PDL-1 and CTLA-4 inhibitors has transformed the landscape of treatment for many tumours, to date, ICIs have been unsuccessful in PDAC, with trials reporting disappointing outcomes. Here, CTLA4 is linked to neoplasm.